Page 29 - Sun Pharma

Sun Pharma net profit up four-fold to Rs 1,242 crore in Dec quarter

The company may also spend more on research and development (R&D) next year owing to clinical trials for new indications of its recently launched product Ilumya and others

Sun Pharma reports nearly four-fold jump in Q3 net profit at Rs 1,242 cr

The company had posted a net profit of Rs 321.57 crore for the corresponding period of the previous fiscal

Sun Pharma promoter meets Sebi chief to clarify on whistleblower complaint

Dilip Shanghvi clarifies stance on various allegations, claims mala fide campaign against him and firm

Sun Pharma to settle Dubai firm loans, shift distribution arm to subsidiary

Sun Pharma in damage control mode after stock loses about 30% of its value since Sept due to corporate governance concerns

Sun Pharma takes steps to ease governance concerns; shares rally over 6%

The move comes after its shares tumbled last week following reports about a complaint by a whistleblower to regulators relating to certain transactions involving the company and an executive director

Sun Pharma jumps 5% on series of clarifications

The drug major said that its domestic formulations distribution shall be transitioned from Aditya Medisales, the current distributor, to a wholly-owned subsidiary of Sun Pharma.

Sun Pharma to make unit distributor for local formulations biz

Sun Pharma had last week asked India's capital markets regulator to look into a media report about an alleged complaint by a whistleblower

Chart Check: What's next for L&T and Sun Pharma as per technical charts

Here's a look at what technical charts indicate for the two buzzing stocks - L&T and Sun Pharma -

Sun Pharma gains 4% after crashing 14% in past two days

The stock recovered 8% from Friday's low after the Sun Pharma urged the markets regulator to examine the role of some media houses with regard to the allegations raised by the whistle-blower.

Sun Pharma's Dilip Shanghvi loses over 60% wealth in four years

Pharma company's valuations have been hit by several issues resulting in the promoter losing nearly Rs 90,000 cr

Sun Pharma moves Sebi as stock dips on fresh whistle-blower allegations

Sun Pharma on Friday urged the markets regulator to examine the role of some media houses with regard to the allegations raised by the whistle-blower

Sun Pharma seeks Sebi help, shares plummet after whistleblower complaint

Shares of Sun Pharma plummeted over 8 per cent that wiped out Rs 8,735 crore from its market valuation

Sun Pharma plunges to six-year low on buzz of fresh whistleblower complaint

According to a news report by financial news website Moneylife, huge transactions took place between Aditya Medisales and private Companies of Sun Pharma's promoters between 2014 and 2017

Sun Pharma acquires Japan's Pola Pharma to expand in dermatology segment

Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables

Sun Pharma up 2% as arm gets relief by US court in patent infringement case

On a year-to-date (YTD) basis, Sun Pharma stock has underperformed the Nifty Pharma index by declining around 28 per cent.

Sun Pharma arm gets relief from US court in patent infringement case

Earlier this year, DUSA, which is wholly-owned by Sun Pharma, filed a lawsuit against the Biofrontera defendants in the US District Court for the District of Massachusetts

Sebi probes whistleblower complaint against Sun Pharma; shares tumble 3%

A whistleblower had last month approached Sebi with a document alleging various irregularities by the company, its promoter Dilip Shanghvi and others

Meet Sudhir Valia, Sun Pharma's director, one of India's prolific investors

His real estate transactions in the last couple of years further bought him into the spotlight

Sun Pharma promoters lose Rs 126 bn in 10 days over insider trading charges

Shares plunge to a five-year low

Sun Pharma hits lowest level since April 2013; falls 33% from 52-week high

The stock hit an over five-year low of Rs 433, down 2%, falling 12% in three days, even though the company made a clarification related to corporate governance and whistleblower issues.